Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

Multikinase inhibitors (MKIs), and particularly tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (CPIs), are currently some of the major breakthroughs in cancer treatment. Proton pump inhibitors (PPIs) revolutionised the treatment of acid-related diseases, but are frequently overus...

Full description

Bibliographic Details
Main Authors: Jean-Luc Raoul, Julien Edeline, Victor Simmet, Camille Moreau-Bachelard, Marine Gilabert, Jean-Sébastien Frénel
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
proton pump inhibitors
cancer
tyrosine kinase inhibitors checkpoint inhibitors
drug interactions
efficacy
Online Access:https://www.mdpi.com/2072-6694/14/5/1156

Internet

https://www.mdpi.com/2072-6694/14/5/1156

Similar Items